Related Experiment Video
Updated: Jul 12, 2025

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
Published on: October 26, 2020
Kidney Intrinsic Mechanisms as Novel Targets in Renovascular Hypertension
Alfonso Eirin1, Alejandro R Chade2, Lilach O Lerman1
1Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN (A.E., L.O.L.).
Insights
Renovascular disease (RVD) causes hypertension and kidney damage. Therapies targeting the kidney
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Vascular Biology
Background:
- Renovascular disease (RVD), often due to renal artery stenosis, is a significant cause of renovascular hypertension and chronic kidney disease.
- RVD can present asymptomatically or progress to severe renal dysfunction, hypertension, and increased cardiovascular risk.
- Atherosclerotic RVD causes renal atrophy, inflammation, and hypoxia, yet the ischemic kidney retains regenerative potential before fibrosis.
Purpose of the Study:
- To review the mechanisms of kidney damage and recovery in renovascular disease (RVD).
- To explore therapeutic opportunities targeting intrinsic repair mechanisms in the ischemic kidney.
- To highlight the potential for therapies aimed at renal parenchyma regeneration.
Main Methods:
- Review of existing literature on renovascular disease (RVD) mechanisms.
- Analysis of animal studies and clinical trials on renal artery revascularization and targeted therapies.
- Synthesis of data on injurious pathways and regenerative capacities in the ischemic kidney.
Main Results:
- Renal artery revascularization has shown inadequate efficacy in fully restoring renal function or blood pressure.
- Therapies targeting the ischemic renal parenchyma show promise for instigating renal regeneration.
- Key injurious mechanisms include oxidative stress, microvascular disease, inflammation, mitochondrial injury, and cellular senescence.
Conclusions:
- Early diagnosis and treatment of RVD are crucial due to the kidney's regenerative potential.
- Targeted therapies addressing specific injury pathways offer a promising approach for RVD management.
- Understanding RVD's intrinsic damage and recovery mechanisms can guide future regenerative strategies.
Abstract:
Almost a hundred years have passed since obstruction of the renal artery has been recognized to raise blood pressure. By now chronic renovascular disease (RVD) due to renal artery stenosis is recognized as a major source of renovascular hypertension and renal disease. In some patients, RVD unaccompanied by noteworthy renal dysfunction or blood pressure elevation may be incidentally identified during peripheral angiography. Nevertheless, in others, RVD might present as a progressive disease associated with diffuse atherosclerosis, leading to loss of renal function, renovascular hypertension, hemodynamic compromise, and a magnified risk for cardiovascular morbidity and mortality. Atherosclerotic RVD leads to renal atrophy, inflammation, and hypoxia but represents a potentially treatable cause of chronic renal failure because until severe fibrosis sets in the ischemic kidney, it retains a robust potential for vascular and tubular regeneration. This remarkable recovery capacity of the kidney begs for early diagnosis and treatment. However, accumulating evidence from both animal studies and randomized clinical trials has convincingly established the inadequate efficacy of renal artery revascularization to fully restore renal function or blood pressure control and has illuminated the potential of therapies targeted to the ischemic renal parenchyma to instigate renal regeneration. Some of the injurious mechanisms identified as potential therapeutic targets included oxidative stress, microvascular disease, inflammation, mitochondrial injury, and cellular senescence. This review recapitulates the intrinsic mechanisms that orchestrate renal damage and recovery in RVD and can be harnessed to introduce remedial opportunities.
Related Concept Videos
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Hypertension and Regulation of Blood Pressure
Hormonal Regulation
Hypertension II: Pathophysiology

